Decnupaz

News

AbbVie's Decnupaz approval will give patients with rare blood cancer BPDCN an alternative to Stemline's Elzonris with a simpler dosing regimen.

News

Pharmacy now represents 25% of employer healthcare spending, and employers are turning to DTC models and nontraditional PBMs to cut costs.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.